Advanced

Intravesical instillations and cancer-specific survival in patients with primary carcinoma in situ of the urinary bladder

Jancke, Georg LU ; Liedberg, Fredrik LU ; Aljabery, Firas; Sherif, Amir; Ströck, Viveka; Malmström, Per Uno LU ; Hosseini Aliabad, Abolfazl and Jahnson, Staffan (2017) In Scandinavian Journal of Urology2013-01-01+01:00 p.1-6
Abstract

Objective: The aim of this study was to evaluate the use of intravesical treatment and cancer-specific survival of patients with primary carcinoma in situ (CIS). Materials and methods: Data acquisition was based on the Swedish National Registry of Urinary Bladder Cancer by selecting all patients with primary CIS. The analysis covered gender, age, hospital type and hospital volume. Intravesical treatment and death due to bladder cancer were evaluated by multivariate logistic regression and multivariate Cox analysis, respectively. Results: The study included 1041 patients (median age at diagnosis 72 years) with a median follow-up of 65 months. Intravesical instillation therapy was given to 745 patients (72%), and 138 (13%) died from... (More)

Objective: The aim of this study was to evaluate the use of intravesical treatment and cancer-specific survival of patients with primary carcinoma in situ (CIS). Materials and methods: Data acquisition was based on the Swedish National Registry of Urinary Bladder Cancer by selecting all patients with primary CIS. The analysis covered gender, age, hospital type and hospital volume. Intravesical treatment and death due to bladder cancer were evaluated by multivariate logistic regression and multivariate Cox analysis, respectively. Results: The study included 1041 patients (median age at diagnosis 72 years) with a median follow-up of 65 months. Intravesical instillation therapy was given to 745 patients (72%), and 138 (13%) died from bladder cancer during the observation period. Male gender [odds ratio (OR) = 1.56, 95% confidence interval (CI) 1.13–2.17] and treatment at county (OR = 1.65, 95% CI 1.17–2.33), university (OR =2.12, 95% CI 1.48–3.03) or high-volume (OR = 1.92, 95% CI 1.34–2.75) hospitals were significantly associated with higher odds of intravesical instillations. The age category ≥80 years had a significantly lower chance of receiving intravesical therapy (OR = 0.44, 95% CI 0.26–0.74) and a significantly higher risk of dying from bladder cancer (hazard ratio = 3.03, 95% CI 1.71–5.35). Conclusion: Significantly more frequent use of intravesical treatment of primary CIS was found for males and for patients treated at county, university and high-volume hospitals. Age ≥80 years was significantly related to less intravesical treatment and poorer cancer-specific survival.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
Cancer-specific survival, intravesical treatment, primary CIS
in
Scandinavian Journal of Urology2013-01-01+01:00
pages
1 - 6
publisher
Taylor & Francis
external identifiers
  • scopus:85016293940
  • wos:000403629400006
ISSN
2168-1805
DOI
10.1080/21681805.2017.1298156
language
English
LU publication?
yes
id
a2819a58-4ec2-42b0-8df7-d181ff5c995b
date added to LUP
2017-05-02 16:33:07
date last changed
2017-09-18 13:33:47
@article{a2819a58-4ec2-42b0-8df7-d181ff5c995b,
  abstract     = {<p>Objective: The aim of this study was to evaluate the use of intravesical treatment and cancer-specific survival of patients with primary carcinoma in situ (CIS). Materials and methods: Data acquisition was based on the Swedish National Registry of Urinary Bladder Cancer by selecting all patients with primary CIS. The analysis covered gender, age, hospital type and hospital volume. Intravesical treatment and death due to bladder cancer were evaluated by multivariate logistic regression and multivariate Cox analysis, respectively. Results: The study included 1041 patients (median age at diagnosis 72 years) with a median follow-up of 65 months. Intravesical instillation therapy was given to 745 patients (72%), and 138 (13%) died from bladder cancer during the observation period. Male gender [odds ratio (OR) = 1.56, 95% confidence interval (CI) 1.13–2.17] and treatment at county (OR = 1.65, 95% CI 1.17–2.33), university (OR =2.12, 95% CI 1.48–3.03) or high-volume (OR = 1.92, 95% CI 1.34–2.75) hospitals were significantly associated with higher odds of intravesical instillations. The age category ≥80 years had a significantly lower chance of receiving intravesical therapy (OR = 0.44, 95% CI 0.26–0.74) and a significantly higher risk of dying from bladder cancer (hazard ratio = 3.03, 95% CI 1.71–5.35). Conclusion: Significantly more frequent use of intravesical treatment of primary CIS was found for males and for patients treated at county, university and high-volume hospitals. Age ≥80 years was significantly related to less intravesical treatment and poorer cancer-specific survival.</p>},
  author       = {Jancke, Georg and Liedberg, Fredrik and Aljabery, Firas and Sherif, Amir and Ströck, Viveka and Malmström, Per Uno and Hosseini Aliabad, Abolfazl and Jahnson, Staffan},
  issn         = {2168-1805},
  keyword      = {Cancer-specific survival,intravesical treatment,primary CIS},
  language     = {eng},
  month        = {03},
  pages        = {1--6},
  publisher    = {Taylor & Francis},
  series       = {Scandinavian Journal of Urology2013-01-01+01:00},
  title        = {Intravesical instillations and cancer-specific survival in patients with primary carcinoma in situ of the urinary bladder},
  url          = {http://dx.doi.org/10.1080/21681805.2017.1298156},
  year         = {2017},
}